Effect of the HCC Liver-Link Intervention (NCT06728293)
🩺 Plain-English Summary (8th-Grade Level)
This study is a pilot, multi-center randomized controlled trial testing the HCC Liver-Link intervention, a culturally tailored, multi-level program designed to reduce racial disparities in hepatocellular carcinoma (HCC) care. The intervention combines: (1) patient education to improve HCC-related disease and treatment knowledge, (2) social needs and substance use screening with referral to social work and community resources, and (3) facilitated access to subspecialty cancer care through a multidisciplinary HCC tumor board. A total of 40 Black patients with Barcelona Clinic Liver Cancer (BCLC) stage 0, A, or downstaged B disease will be randomized to receive either the HCC Liver-Link intervention or usual care and followed for 6 months or until liver transplant waitlisting. Primary outcomes are time to receipt of curative therapies (liver transplantation or resection) and change in HCC-related knowledge. Findings will inform development of larger interventions to eliminate racial disparities in HCC outcomes.
Who can join: Review the eligibility criteria below.
Location: Indiana University School of Medicine — Indianapolis, Indiana
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
- Liver Link (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Indiana University School of Medicine — Indianapolis, Indiana
- Johns Hopkins University — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (317) 278-6424
Email: samussel@iu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HCC
- GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC — Baltimore, Maryland
- Optimizing Y90 Therapy for Radiation Lobectomy — Jacksonville, Florida
- Y-90 Treatment Response Using Transarterial Radioembolization — Philadelphia, Pennsylvania
- Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC — Atlanta, Georgia
- CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules — Ann Arbor, Michigan
Explore by condition: All HCC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.